Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | KCNH3 | Q9ULD8 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931717 | 0.89 | ALDH1A1 (0.50) | ALDH1A1MAPTL3MBTL1KCNH3LMNA | |
| SCHEMBL7563367 | 0.89 | KCNH3 (0.64) | ALDH1A1MAPTL3MBTL1KCNH3LMNA | |
| SCHEMBL30462887 | 0.88 | ALDH1A1 (0.48) | ALDH1A1MAPTL3MBTL1KCNH3LMNA | |
| SCHEMBL9526296 | 0.88 | KCNH3 (0.62) | ALDH1A1MAPTL3MBTL1KCNH3LMNA | |
| SCHEMBL30462888 | 0.88 | ALDH1A1 (0.48) | ALDH1A1MAPTL3MBTL1KCNH3LMNA | |
| SCHEMBL25192583 | 0.88 | ALDH1A1 (0.48) | ALDH1A1MAPTL3MBTL1KCNH3LMNA | |
| SCHEMBL9015900 | 0.88 | KCNH3 (0.51) | ALDH1A1MAPTL3MBTL1KCNH3LMNA | |
| SCHEMBL19628899 | 0.88 | ALDH1A1 (0.48) | ALDH1A1MAPTL3MBTL1KCNH3LMNA | |
| SCHEMBL14982724 | 0.88 | KCNH3 (0.51) | ALDH1A1MAPTL3MBTL1KCNH3LMNA | |
| SCHEMBL26815529 | 0.88 | ALDH1A1 (0.48) | ALDH1A1MAPTL3MBTL1KCNH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111650811-B | White photosensitive film and preparation method and application thereof | 上海孚赛特新材料股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | CIPHER PHARMACEUTICALS INC. (CA) | 2019-05-02 | — | — | US | disclosed |
| CN-104020622-B | Display particle, display particle dispersion, display medium and display device | 电子墨水公司 | 2018-07-24 | — | — | CN | disclosed |
| US-9907765-B2 | Treatment of connective tissue diseases of the skin | CIPHER PHARMACEUTICALS INC. (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2017-06-08 | — | — | US | disclosed |
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEVELOPMENT A/S (DK) | 2013-09-12 | — | — | US | disclosed |
| US-8426475-B2 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S (DK) | 2013-04-23 | — | — | US | disclosed |
| EP-1719507-B1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | ASTION DEV AS (DK) | 2010-07-14 | — | — | EP | disclosed |
| WO-2006108424-A9 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEV AS (DK) | 2007-08-09 | — | — | WO | disclosed |
| EP-1719507-A1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | Astion Development A/S (DK) | 2006-11-08 | — | — | EP | disclosed |
| EP-1496917-A1 | COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR THE TREATMENT IMMUNOMODULATORY DISORDERS | Astion Development APS (DK) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003097073-A1 | COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR THE TREATMENT IMMUNOMODULATORY DISORDERS | ASTION DEVELOPMENT A/S (DK) | 2003-11-27 | — | — | WO | disclosed |
| US-6525150-B1 | Such as vanadium 2,2'-thiobis(6-t-butyl-4-methylphenyl) oxychloride complex, trimethylaluminum and N,N-dimethyl-anilinium tetrakis(pentafluorophenyl)borate; high degree of copolymerization | JSR CORPORATION (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1046654-A1 | Olefin polymerization catalysts and olefin polymer production methods using said olefin polymerization catalysts | JSR Corporation (JP) | 2000-10-25 | — | — | EP | disclosed |
| WO-1995019336-A1 | PHENYL ETHANOL AMINE ETHERS AND USES THEREOF AS β-ADRENO-RECEPTOR AGONISTS | IOVIS BIOMEDICAL AND PHARMACEUTICAL CONSULTANTS (NL) | 1995-07-20 | — | — | WO | disclosed |
| EP-0308745-B1 | THICKENED MOULDING COMPOSITION | BASF Aktiengesellschaft (DE) | 1992-11-19 | — | — | EP | disclosed |
| US-5047455-A | Containing liquid, polymerizable reactive system, isocyanate, initiator and additive shelf life | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | disclosed |
| EP-0308745-A2 | Thickened moulding composition | BASF Aktiengesellschaft (DE) | 1989-03-29 | — | — | EP | disclosed |
| US-4095022-A | PHOSPHORUS COMPOUNDS, SILICA-ALUMINA CATALYST | TEXACO DEVELOPMENT CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
| US-4026935-A | FROM N-(HYDROXYALKYL)-MORPHOLINE COMPOUND, SILICA-ALUMINA CATALYST | TEXACO DEVELOPMENT CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ALDH1A1 1389/4885MAPT 3107/4885L3MBTL1 2856/4885 |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ALDH1A1 1389/4885MAPT 3107/4885L3MBTL1 2856/4885 |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ALDH1A1 1389/4885MAPT 3107/4885L3MBTL1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.